Skip to main content
SpringerLink
Log in

Cell Surface Co-signaling Molecules in the Control of Innate and Adaptive Cancer Immunity

  • Chapter
  • First Online:
Innate Immune Regulation and Cancer Immunotherapy

  • 1795 Accesses

Abstract

Recent advances in cancer immunotherapy have focused on manipulating co-signaling pathways to direct or fine-tune antitumor immune responses. This is based on the findings that co-signaling pathways are pivotal in positive and negative regulation of innate and adaptive immunity to antigens. Importantly, cancer cells as well as cells in cancer microenvironments often aberrantly express co-signaling molecules to evade tumor immunity. We will focus our discussion on two co-signaling pathways including CD137/CD137L and B7-H1/PD-1. The data from animal models and clinical trials indicate that monoclonal antibodies and recombinant proteins targeting these co-signaling molecules are able to stimulate antitumor immune responses or ablate immune suppression. Co-signaling molecules thus add a new modality for mechanism-based design of combined immunotherapy in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ahmadzadeh M et al (2009) Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114(8):1537–1544

    Article  PubMed  CAS  Google Scholar 

  • Azuma T et al (2008) B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111(7):3635–3643

    Article  PubMed  CAS  Google Scholar 

  • Barber DL et al (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077):682–687

    Article  PubMed  CAS  Google Scholar 

  • Baxter AG, Hodgkin PD (2002) Activation rules: the two-signal theories of immune activation. Nat Rev Immunol 2(6):439–446

    PubMed  CAS  Google Scholar 

  • Bertram EM et al (2002) Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection. J Immunol 168(8):3777–3785

    PubMed  CAS  Google Scholar 

  • Butte MJ et al (2007) Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27(1):111–122

    Article  PubMed  CAS  Google Scholar 

  • Chemnitz JM et al (2004) SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173(2):945–954

    PubMed  CAS  Google Scholar 

  • Chen L (2004) Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4(5):336–347

    Article  PubMed  CAS  Google Scholar 

  • Cheuk AT et al (2004) Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther 11(3):215–226

    Article  PubMed  CAS  Google Scholar 

  • Choi BK et al (2007) Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy. Cancer Res 67(18):8891–8899

    Article  PubMed  CAS  Google Scholar 

  • Croft M (2003) Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 3(8):609–620

    Article  PubMed  CAS  Google Scholar 

  • Dawicki W, Watts TH (2004) Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo. Eur J Immunol 34(3):743–751

    Article  PubMed  CAS  Google Scholar 

  • Dawicki W et al (2004) 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses. J Immunol 173(10):5944–5951

    PubMed  CAS  Google Scholar 

  • Dong H, Chen L (2003) B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med 81(5):281–287

    PubMed  CAS  Google Scholar 

  • Dong H, Chen X (2006) Immunoregulatory role of B7-H1 in chronicity of inflammatory responses. Cell Mol Immunol 3(3):179–187

    PubMed  CAS  Google Scholar 

  • Dong H et al (1999) B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5(12):1365–1369

    Article  PubMed  CAS  Google Scholar 

  • Dong H et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8(8):793–800

    PubMed  CAS  Google Scholar 

  • Dong H et al (2003) Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest 111(3):363–370

    PubMed  CAS  Google Scholar 

  • Dudley ME et al (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23(10):2346–2357

    Article  PubMed  CAS  Google Scholar 

  • Foell J et al (2003) CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J Clin Invest 111(10):1505–1518

    PubMed  CAS  Google Scholar 

  • Foell JL et al (2004) Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance. Immunology 113(1):89–98

    Article  PubMed  CAS  Google Scholar 

  • Freeman GJ (2008) Structures of PD-1 with its ligands: sideways and dancing cheek to cheek. Proc Natl Acad Sci USA 105(30):10275–10276

    Article  PubMed  CAS  Google Scholar 

  • Freeman GJ et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027–1034

    Article  PubMed  CAS  Google Scholar 

  • Goldberg MV et al (2007) Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood 110(1):186–192

    Article  PubMed  CAS  Google Scholar 

  • Goodwin RG et al (1993) Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur J Immunol 23(10):2631–2641

    Article  PubMed  CAS  Google Scholar 

  • Gray JC et al (2008) Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies. Eur J Immunol 38(9):2499–2511

    Article  PubMed  CAS  Google Scholar 

  • Hirano F et al (2005) Blockade of B7-H1 and PD-1 by monoclonal antibodies potaentiates cancer therapeutic immunity. Cancer Res 65(3):1089–1096

    PubMed  CAS  Google Scholar 

  • Houot R et al (2009) Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 114(16):3431–3438

    Article  PubMed  CAS  Google Scholar 

  • Ishida Y et al (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11(11):3887–3895

    PubMed  CAS  Google Scholar 

  • June CH (2007) Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117(6):1466–1476

    Article  PubMed  CAS  Google Scholar 

  • Kim YH et al (2009) Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy. Mol Cancer Ther 8(2):469–478

    Article  PubMed  CAS  Google Scholar 

  • Kober J et al (2008) The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur J Immunol 38(10):2678–2688

    Article  PubMed  CAS  Google Scholar 

  • Kryczek I et al (2007) Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 67(18):8900–8905

    Article  PubMed  CAS  Google Scholar 

  • Kumar H et al (2009) Toll-like receptors and innate immunity. Biochem Biophys Res Commun 388(4):621–625

    Article  PubMed  CAS  Google Scholar 

  • Kwon BS, Weissman SM (1989) cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci USA 86(6):1963–1967

    Article  PubMed  CAS  Google Scholar 

  • Kwon BS et al (2002) Immune responses in 4-1BB (CD137)-deficient mice. J Immunol 168(11):5483–5490

    PubMed  CAS  Google Scholar 

  • Latchman Y et al (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2(3):261–268

    Article  PubMed  CAS  Google Scholar 

  • Lee HK, Iwasaki A (2007) Innate control of adaptive immunity: dendritic cells and beyond. Semin Immunol 19(1):48–55

    Article  PubMed  CAS  Google Scholar 

  • Lee SC et al (2009a) Stimulation of the molecule 4-1BB enhances host defense against Listeria monocytogenes infection in mice by inducing rapid infiltration and activation of neutrophils and monocytes. Infect Immun 77(5):2168–2176

    Article  PubMed  CAS  Google Scholar 

  • Lee SW et al (2009b) Hypercostimulation through 4-1BB distorts homeostasis of immune cells. J Immunol 182(11):6753–6762

    Article  PubMed  CAS  Google Scholar 

  • Lynch DH (2008) The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev 222:277–286

    Article  PubMed  CAS  Google Scholar 

  • Melero I et al (2007) Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 7(2):95–106

    Article  PubMed  CAS  Google Scholar 

  • Melero I et al (2008) Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci 29(8):383–390

    Article  PubMed  CAS  Google Scholar 

  • Melero I et al (2009) Palettes of vaccines and immunostimulatory monoclonal antibodies for combination. Clin Cancer Res 15(5):1507–1509

    Article  PubMed  CAS  Google Scholar 

  • Muller D et al (2008) A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy. J Immunother 31(8):714–722

    Article  PubMed  Google Scholar 

  • Murillo O et al (2008) Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res 14(21):6895–6906

    Article  PubMed  CAS  Google Scholar 

  • Myers LM, Vella AT (2005) Interfacing T-cell effector and regulatory function through CD137 (4-1BB) co-stimulation. Trends Immunol 26(8):440–446

    Article  PubMed  CAS  Google Scholar 

  • Narazaki H et al (2010) CD137 anonist antibody prevents cancer recurrence: Contribution of CD137 on both hematopoietic and non-hematopoietic cells. Blood 115(10):1941–1948

    Article  PubMed  CAS  Google Scholar 

  • Okudaira K et al (2009) Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int J Oncol 35(4):741–749

    PubMed  CAS  Google Scholar 

  • Old LJ (1988) Tumor necrosis factor. Sci Am 258(5):59–60; 69–75

    Google Scholar 

  • Paulos CM et al (2008) Adoptive immunotherapy: good habits instilled at youth have long-term benefits. Immunol Res 42(1–3):182–196

    Article  PubMed  Google Scholar 

  • Riley JL (2009) PD-1 signaling in primary T cells. Immunol Rev 229(1):114–125

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg SA et al (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8(4):299–308

    Article  PubMed  CAS  Google Scholar 

  • Sansom DM (2000) CD28, CTLA-4 and their ligands: who does what and to whom? Immunology 101(2):169–177

    Article  PubMed  CAS  Google Scholar 

  • Schabowsky RH et al (2009). A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab-associated severe toxicity. Vaccine 28(2):512–22

    Article  PubMed  CAS  Google Scholar 

  • Seo SK et al (2004) 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 10(10):1088–1094

    Article  PubMed  CAS  Google Scholar 

  • Sharma RK et al (2009) Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Res 69(10):4319–4326

    Article  PubMed  CAS  Google Scholar 

  • Shi W, Siemann DW (2006) Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. Anticancer Res 26(5A):3445–3453

    PubMed  CAS  Google Scholar 

  • Sun Y et al (2002a) Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med 8(12):1405–1413

    Article  PubMed  CAS  Google Scholar 

  • Sun Y et al (2002b) Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol 168(3):1457–1465

    PubMed  CAS  Google Scholar 

  • Tamura H et al (2003) Immunology of B7-H1 and its roles in human diseases. Int J Hematol 78(4):321–328

    Article  PubMed  CAS  Google Scholar 

  • Tan JT et al (1999) 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses. J Immunol 163(9):4859–4868

    PubMed  CAS  Google Scholar 

  • Teng MW et al (2009) CD1d-based combination therapy eradicates established tumors in mice. J Immunol 183(3):1911–1920

    Article  PubMed  CAS  Google Scholar 

  • Tseng SY et al (2001) B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 193(7):839–846

    Article  PubMed  CAS  Google Scholar 

  • Uno T et al (2006) Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 12(6):693–698

    Article  PubMed  CAS  Google Scholar 

  • Wang S et al (2003) Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med 197(9):1083–1091

    Article  PubMed  CAS  Google Scholar 

  • Wang C et al (2009a) Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev 229(1):192–215

    Article  PubMed  CAS  Google Scholar 

  • Wang W et al (2009b) PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol 21(9):1065–1077

    Article  PubMed  CAS  Google Scholar 

  • Watts TH (2005) TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23:23–68

    Article  PubMed  CAS  Google Scholar 

  • Wilcox RA et al (2002a) Cutting edge: expression of functional CD137 receptor by dendritic cells. J Immunol 168(9):4262–4267

    PubMed  CAS  Google Scholar 

  • Wilcox RA et al (2002b) Impaired infiltration of tumor-specific cytolytic T cells in the absence of interferon-gamma despite their normal maturation in lymphoid organs during CD137 monoclonal antibody therapy. Cancer Res 62(15):4413–4418

    PubMed  CAS  Google Scholar 

  • Wilcox RA et al (2002c) Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 109(5):651–659

    PubMed  CAS  Google Scholar 

  • Wilcox RA et al (2002d) Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol 169(8):4230–4236

    PubMed  CAS  Google Scholar 

  • Wu K et al (2009) Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res 69(20):8067–8075

    Article  PubMed  CAS  Google Scholar 

  • Xiao H et al (2007) Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo. Clin Cancer Res 13(6):1823–1830

    Article  PubMed  CAS  Google Scholar 

  • Zhang H et al (2007) 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol 179(7):4910–4918

    PubMed  CAS  Google Scholar 

  • Zhu G et al (2001) Progressive depletion of peripheral B lymphocytes in 4-1BB (CD137) ligand/I-Ealpha)-transgenic mice. J Immunol 167(5):2671–2676

    PubMed  CAS  Google Scholar 

  • Zhu Y et al (2007) CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype. Blood 109(11):4882–4889

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Stasya Zarling & Lieping Chen

Authors
  1. Stasya Zarling
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lieping Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lieping Chen .

Editor information

Editors and Affiliations

  1. Center for Cell & Gene Therapy, Baylor College of Medicine, Baylor Plaza 1, Houston, 77030, Texas, USA

    Rongfu Wang

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Zarling, S., Chen, L. (2012). Cell Surface Co-signaling Molecules in the Control of Innate and Adaptive Cancer Immunity. In: Wang, R. (eds) Innate Immune Regulation and Cancer Immunotherapy. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-9914-6_14

Download citation

Publish with us

Policies and ethics

Search

Navigation